Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of FKS518 vs Prolia in Postmenopausal Osteoporosis (LUMIADE-3)
NCT04934072Phase 3Completed
- Sponsor
- Fresenius Kabi
- Start
- Jun 2021
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of DenOsteoRel in postmenopausal osteoporosis (2 arms), sponsored by Fresenius Kabi. Primary endpoint: Percentage Change From Baseline in Lumbar Spine Bone Mineral Density at Week 52. Started Jun 2021; status: completed.
02
Drugs
DenOsteoRel
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT04934072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934072.